Sanjib Basu
Affiliations: | Mathematical Sciences | Northern Illinois University, DeKalb, IL, United States |
Area:
StatisticsGoogle:
"Sanjib Basu"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chaudhry T, Krishnan V, Donaldson AE, et al. (2023) Conditional survival analysis of patients with resected non-small cell lung cancer. Jtcvs Open. 16: 948-959 |
| Seder CW, Basu S, Ramsay T, et al. (2019) A Prolonged Air Leak Score for Lung Cancer Resection: An Analysis of the STS GTSD. The Annals of Thoracic Surgery |
| Burkart M, Schieber M, Basu S, et al. (2019) Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. British Journal of Haematology |
| Bhatt PK, Fughhi I, Basu S, et al. (2019) Mature, real world progression-free survival (PFS) and overall survival (OS) milestones in stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) followed by pem+/-bevacizumab(Bev) maintenance. Journal of Clinical Oncology. 37 |
| Kollipara R, Fughhi I, Batus M, et al. (2019) Decreasing BMI/weight immediately prior to starting anti-PD-1/PDL-1 monoclonal antibodies for treatment for stage IV non-small cell lung cancer is associated with shorter progression-free survival. Journal of Clinical Oncology. 37 |
| Randall M, Basu S, Batus M, et al. (2019) Correlating the effects of VeriStrat result, anti-PD1 therapy, and neutrophil-to-lymphocyte ratio (NLR) on progression-free survival (PFS) in patients with stage IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 37 |
| Multani M, Tarhoni I, Fughhi I, et al. (2019) Changes in skeletal muscle mass during PD-1 and PD-L1 checkpoint inhibitor therapy in advanced-stage non-small cell lung cancer patients. Journal of Clinical Oncology. 37 |
| Lobato GC, Fidler MJ, Fialkoff JD, et al. (2019) Associations between baseline serum biomarker levels and cachexia/precachexia in pretreated non-small cell lung cancer (NSCLC) patients. Journal of Clinical Oncology. 37: 3054-3054 |
| Tarhoni I, Fidler MJ, Fughhi I, et al. (2019) Abstract 404: Prognostic value of soluble and cell surface immune-checkpoint molecules in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-1/-L1 immunotherapy Cancer Research. 79: 404-404 |
| Randall M, Kollipara R, Basu S, et al. (2019) P1.05 Clinical Factors Associated with Progression in Previously Treated Patients with Metastatic NSCLC on ANTI-PD-1 Therapy Journal of Thoracic Oncology. 14 |